Literature DB >> 22370919

In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2010-2011 season in Japan.

Hideyuki Ikematsu1, Naoki Kawai, Seizaburo Kashiwagi.   

Abstract

The half maximal inhibitory concentration (IC(50)) of four neuraminidase inhibitors (NAIs), oseltamivir, zanamivir, laninamivir, and peramivir; was measured using influenza viruses isolated in the 2010-2011 influenza season in Japan. Clinical samples for viral isolation were obtained from nasal aspiration, nasopharyngeal swab, or self-blown nasal discharge and cultured with Madin-Darby canine kidney cells. The type and subtype of H3N2 or B were determined by reverse transcriptase polymerase chain reaction (RT-PCR). For the A(H1N1)pdm09 virus, the subtype was determined by real-time RT-PCR. IC(50)s to oseltamivir carboxylate, zanamivir, laninamivir, and peramivir were determined by a fluorescence-based neuraminidase inhibition assay. Influenza viruses were isolated from 269 patients. A(H1N1)pdm09, H3N2, and B were isolated from 185, 54, and 30 patients, respectively. The geometric means of IC(50) for oseltamivir were 0.86 and 0.73 nM to A (H1N1) pdm09, except for the two outlier viruses described below and H3N2, respectively, and 33.12 nM for B. The geometric means of IC(50) for the other three NAIs were lowest to A(H1N1)pdm09 and highest to B. Two A(H1N1)pdm09 isolates showed very high IC(50) values for oseltamivir (840 and 600 nM) and peramivir (19 and 24 nM). No isolate showed significantly high IC(50) values for zanamivir or laninamivir. Continuous surveillance against the emergence or spread of influenza virus with high IC(50) values for anti-influenza drugs is important.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22370919     DOI: 10.1007/s10156-012-0377-8

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  3 in total

1.  Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011-2012 season.

Authors:  Naoko Koseki; Miki Kaiho; Hideaki Kikuta; Koji Oba; Takehiro Togashi; Tadashi Ariga; Nobuhisa Ishiguro
Journal:  Influenza Other Respir Viruses       Date:  2013-08-19       Impact factor: 4.380

2.  Increased symptom severity but unchanged neuraminidase inhibitor effectiveness for A(H1N1)pdm09 in the 2010-2011 season: comparison with the previous season and with seasonal A(H3N2) and B.

Authors:  Naoki Kawai; Hideyuki Ikematsu; Takashi Kawashima; Tetsunari Maeda; Hiroshi Ukai; Nobuo Hirotsu; Norio Iwaki; Seizaburo Kashiwagi
Journal:  Influenza Other Respir Viruses       Date:  2012-08-16       Impact factor: 4.380

3.  Long-acting Neuraminidase Inhibitor Laninamivir Octanoate as Post-exposure Prophylaxis for Influenza.

Authors:  Seizaburo Kashiwagi; Akira Watanabe; Hideyuki Ikematsu; Mitsutoshi Uemori; Shinichiro Awamura
Journal:  Clin Infect Dis       Date:  2016-04-26       Impact factor: 9.079

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.